BioNTech Announces Second Quarter 2020 Financial Results and Corporate Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BioNTech SE (BNTX) Reports Q2 Loss of $0.38
August 11, 2020 6:05 AM EDTBioNTech SE (NASDAQ: BNTX) reported Q2 EPS of ($0.38), versus ($0.24) reported last year.
Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was 41.8 million for the three months ended June 30, 2020, compared to 25.8 million for the three months ended June 30, 2019. For the period of six months ended June 30, 2020, total revenue was 69.4 million, compared to 51.9 million for the comparative prior year period. The revenue from collaboration agreements overall increased due to the recognition of revenue from our new collaboration agreements signed with Pfizer and Fosun Pharma as part of the Companys BNT162 vaccine program against... More
